Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancer
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-C000000151
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Intestinal pneumonia or lung fibrosis 2) History of severe drug allergic reaction 3) Severe infection and complication (cardio insufficiency or hemorrhage etc.) 4) Severe diarrhea 5) Bowel obstruction,ileus 6) Symptomatic brain metastasis 7) History of other malignancy 8) Pregnant women or women willing child-bearing 9) No regulatory condition because of psychological disease 10) Inadequate condition diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (Primary Endpoint) Response rate
- Secondary Outcome Measures
Name Time Method (Secondary Endpoint) Overall survival, One year survival, Time to progression, disease control rate, safety